請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20351完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 梁碧惠 | zh_TW |
| dc.contributor.author | 劉奕辰 | zh_TW |
| dc.contributor.author | I-Chen Liu | en |
| dc.date.accessioned | 2021-06-08T02:45:58Z | - |
| dc.date.available | 2023-11-20 | - |
| dc.date.copyright | 2018-03-29 | - |
| dc.date.issued | 2017 | - |
| dc.date.submitted | 2002-01-01 | - |
| dc.identifier.citation | 1. Anderson, W. F.; Chatterjee, N.; Ershler, W. B.; Brawley, O. W., Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database. Breast Cancer Res. Treat. 2002, 76 (1), 27-36.
2. Liu, C.-Y.; Wu, C.-Y.; Petrossian, K.; Huang, T.-T.; Tseng, L.-M.; Chen, S., Treatment for the endocrine resistant breast cancer: Current options and future perspectives. J. Steroid Biochem. Mol. Biol. 2017. 3. Liehr, J. G., Is Estradiol a Genotoxic Mutagenic Carcinogen?1. Endocrine Reviews 2000, 21 (1), 40-54. 4. Cavalieri, E.; Frenkel, K.; Liehr, J. G.; Rogan, E.; Roy, D., Chapter 4: Estrogens as Endogenous Genotoxic Agents—DNA Adducts and Mutations. JNCI Monographs 2000, 2000 (27), 75-94. 5. Yue, W.; Santen, R. J.; Wang, J. P.; Li, Y.; Verderame, M. F.; Bocchinfuso, W. P.; Korach, K. S.; Devanesan, P.; Todorovic, R.; Rogan, E. G.; Cavalieri, E. L., Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J. Steroid Biochem. Mol. Biol. 2003, 86 (3), 477-486. 6. H.J. Smith, C. S., Enzymes and Their Inhibitors: Drug Development, CRC press, London. 2004. 7. Mueller, J. W.; Gilligan, L. C.; Idkowiak, J.; Arlt, W.; Foster, P. A., The Regulation of Steroid Action by Sulfation and Desulfation. Endocrine Reviews 2015, 36 (5), 526-563. 8. Pasqualini, J. R.; Gelly, C.; Nguyen, B. L.; Vella, C., Importance of estrogen sulfates in breast cancer. J. Steroid Biochem. 1989, 34 (1), 155-163. 9. Atul Purohit, P. A. F., Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers. J. Endocrinol 2012, 212, 99-110. . 10. Early Breast Cancer Trialists' Collaborative, G., Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. The Lancet 2011, 378 (9793), 771-784. 11. Vogel, C. L.; Johnston, M. A.; Capers, C.; Braccia, D., Toremifene for Breast Cancer: A Review of 20 Years of Data. Clin. Breast Cancer 2014, 14 (1), 1-9. 12. Henry, N. L.; Giles, J. T.; Ang, D.; Mohan, M.; Dadabhoy, D.; Robarge, J.; Hayden, J.; Lemler, S.; Shahverdi, K.; Powers, P.; Li, L.; Flockhart, D.; Stearns, V.; Hayes, D. F.; Storniolo, A. M.; Clauw, D. J., Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res. Treat. 2008, 111 (2), 365-372. 13. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. The Lancet 2015, 386 (10001), 1341-1352. 14. Amir, E.; Seruga, B.; Niraula, S.; Carlsson, L.; Ocaña, A., Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis. J. Natl. Cancer Inst. 2011, 103 (17), 1299-1309. 15. Breast Cancer, Version 1.2017. J. Natl. Compr. Canc. Netw. 2017, (15), 433-451. 16. Foster, P. A.; Chander, S. K.; Newman, S. P.; Woo, L. W. L.; Sutcliffe, O. B.; Bubert, C.; Zhou, D.; Chen, S.; Potter, B. V. L.; Reed, M. J.; Purohit, A., A New Therapeutic Strategy against Hormone-Dependent Breast Cancer: The Preclinical Development of a Dual Aromatase and Sulfatase Inhibitor. Clin. Cancer Res. 2008, 14 (20), 6469-6477. 17. Clarke, R.; Liu, M. C.; Bouker, K. B.; Gu, Z.; Lee, R. Y.; Zhu, Y.; Skaar, T. C.; Gomez, B.; O'Brien, K.; Wang, Y.; Hilakivi-Clarke, L. A., Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 0000, 22 (47), 7316-7339. 18. Stengel, C.; Newman, S. P.; Day, J. M.; Tutill, H. J.; Reed, M. J.; Purohit, A., Effects of mutations and glycosylations on STS activity: A site-directed mutagenesis study. Mol. Cell. Endocrinol. 2008, 283 (1), 76-82. 19. Atul Purohit, P. A. F., Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers. J Endocrinol 2012, (212), 99-110. 20. Francisco G. Hernandez-Guzman, T. H., Walter Pangborn, Yoshio Osawa, Debashis Ghosh, Structure of Human Estrone Sulfatase Suggests Functional Roles of Membrane Association. J Biol Chem 2003, 278, 22989–97. 21. Maltais, R.; Poirier, D., Steroid sulfatase inhibitors: A review covering the promising 2000–2010 decade. Steroids 2011, 76 (10), 929-948. 22. Ghosh, D., Human sulfatases: A structural perspective to catalysis. Cell. Mol. Life Sci. 2007, 64 (15), 2013-2022. 23. Chetrite, G. S.; Cortes-Prieto, J.; Philippe, J. C.; Wright, F.; Pasqualini, J. R., Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J. Steroid Biochem. Mol. Biol. 2000, 72 (1), 23-27. 24. Utsumi, T.; Yoshimura, N.; Takeuchi, S.; Maruta, M.; Maeda, K.; Harada, N., Elevated steroid sulfatase expression in breast cancers. J. Steroid Biochem. Mol. Biol. 2000, 73 (3), 141-145. 25. Howarth, N. M.; Purohit, A.; Reed, M. J.; Potter, B. V. L., Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J. Med. Chem. 1994, 37 (2), 219-221. 26. Pui-Kai, L.; Pillai, R.; Young, B. L.; Bender, W. H.; Martino, D. M.; Lin, F.-T., Synthesis and biochemical studies of estrone sulfatase inhibitors. Steroids 1993, 58 (3), 106-111. 27. Dibbelt, L.; Li, P.-K.; Pillai, R.; Knuppen, R., Inhibition of human placental sterylsulfatase by synthetic analogs of estrone sulfate. J. Steroid Biochem. Mol. Biol. 1994, 50 (5), 261-266. 28. Shah, R.; Singh, J.; Singh, D.; Jaggi, A. S.; Singh, N., Sulfatase inhibitors for recidivist breast cancer treatment: A chemical review. Eur. J. Med. Chem. 2016, 114, 170-190. 29. Ishida, H.; Nakata, T.; Sato, N.; Li, P.-K.; Kuwabara, T.; Akinaga, S., Inhibition of steroid sulfatase activity and cell proliferation in ZR-75-1 and BT-474 human breast cancer cells by KW-2581 in vitro and in vivo. Breast Cancer Res. Treat. 2007, 104 (2), 211-219. 30. Ciobanu, L. C.; Boivin, R. P.; Luu-The, V.; Labrie, F.; Poirier, D., Potent Inhibition of Steroid Sulfatase Activity by 3-O-Sulfamate 17α-Benzyl(or 4‘-tert-butylbenzyl)estra-1,3,5(10)-trienes: Combination of Two Substituents at Positions C3 and C17α of Estradiol. J. Med. Chem. 1999, 42 (12), 2280-2286. 31. Reed, J. E.; Lawrence Woo, L. W.; Robinson, J. J.; Leblond, B.; Leese, M. P.; Purohit, A.; Reed, M. J.; Potter, B. V. L., 2-Difluoromethyloestrone 3-O-sulphamate, a highly potent steroid sulphatase inhibitor. Biochem. Biophys. Res. Commun. 2004, 317 (1), 169-175. 32. Leese, M. P.; Leblond, B.; Newman, S. P.; Purohit, A.; Reed, M. J.; Potter, B. V. L., Anti-cancer activities of novel D-ring modified 2-substituted estrogen-3-O-sulfamates. J. Steroid Biochem. Mol. Biol. 2005, 94 (1), 239-251. 33. Potter, B. V. L. R., M. J., Oestrogen-17-Sulfamates as Inhibitors of Steroid Sulfatase. U.S. Pat. Appl. US 2003203855 A1 2003. 34. Bubert, C.; Leese, M. P.; Mahon, M. F.; Ferrandis, E.; Regis-Lydi, S.; Kasprzyk, P. G.; Newman, S. P.; Ho, Y. T.; Purohit, A.; Reed, M. J.; Potter, B. V. L., 3,17-Disubstituted 2-Alkylestra-1,3,5(10)-trien-3-ol Derivatives: Synthesis, In Vitro and In Vivo Anticancer Activity. J. Med. Chem. 2007, 50 (18), 4431-4443. 35. Leese, M. P.; Leblond, B.; Smith, A.; Newman, S. P.; Di Fiore, A.; De Simone, G.; Supuran, C. T.; Purohit, A.; Reed, M. J.; Potter, B. V. L., 2-Substituted Estradiol Bis-sulfamates, Multitargeted Antitumor Agents: Synthesis, In Vitro SAR, Protein Crystallography, and In Vivo Activity. J. Med. Chem. 2006, 49 (26), 7683-7696. 36. Fischer, D. S.; Woo, L. W. L.; Mahon, M. F.; Purohit, A.; Reed, M. J.; Potter, B. V. L., D-Ring Modified Estrone Derivatives as Novel Potent Inhibitors of Steroid Sulfatase. Bioorg. Med. Chem. 2003, 11 (8), 1685-1700. 37. Ciobanu, L. C.; Luu-The, V.; Martel, C.; Labrie, F.; Poirier, D., Inhibition of Estrone Sulfate-induced Uterine Growth by Potent Nonestrogenic Steroidal Inhibitors of Steroid Sulfatase. Cancer Res. 2003, 63 (19), 6442-6446. 38. Ciobanu, L. C.; Boivin, R. P.; Luu-The, V.; Poirier, D., 3β-Sulfamate Derivatives of C19 and C21 Steroids Bearing a t -Butylbenzyl or a Benzyl Group: Synthesis and Evaluation as Non-estrogenic and Non-androgenic Steroid Sulfatase Inhibitors. J. Enzyme Inhib. Med. Chem. 2003, 18 (1), 15-26. 39. Numazawa, M.; Tominaga, T.; Watari, Y.; Tada, Y., Inhibition of estrone sulfatase by aromatase inhibitor-based estrogen 3-sulfamates. Steroids 2006, 71 (5), 371-379. 40. Rasmussen, L. M.; Zaveri, N. T.; Stenvang, J.; Peters, R. H.; Lykkesfeldt, A. E., A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer. Breast Cancer Res. Treat. 2007, 106 (2), 191-203. 41. El-Gamal, M. I.; Semreen, M. H.; Foster, P. A.; Potter, B. V. L., Design, synthesis, and biological evaluation of new arylamide derivatives possessing sulfonate or sulfamate moieties as steroid sulfatase enzyme inhibitors. Bioorg. Med. Chem. 2016, 24 (12), 2762-2767. 42. Ouellet, C.; Maltais, R.; Ouellet, É.; Barbeau, X.; Lagüe, P.; Poirier, D., Discovery of a sulfamate-based steroid sulfatase inhibitor with intrinsic selective estrogen receptor modulator properties. Eur. J. Med. Chem. 2016, 119, 169-182. 43. Daśko, M.; Rachon, J.; Masłyk, M.; Kubiński, K.; Demkowicz, S., Synthesis and biological evaluation of N-acylated tyramine sulfamates containing C–F bonds as steroid sulfatase inhibitors. Chem. Biol. Drug Des. 2017, 90 (1), 156-161. 44. Daśko, M.; Przybyłowska, M.; Rachon, J.; Masłyk, M.; Kubiński, K.; Misiak, M.; Składanowski, A.; Demkowicz, S., Synthesis and biological evaluation of fluorinated N-benzoyl and N-phenylacetoyl derivatives of 3-(4-aminophenyl)-coumarin-7-O-sulfamate as steroid sulfatase inhibitors. Eur. J. Med. Chem. 2017, 128, 79-87. 45. Salah, M.; Abdelsamie, A. S.; Frotscher, M., First Dual Inhibitors of Steroid Sulfatase (STS) and 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1): Designed Multiple Ligands as Novel Potential Therapeutics for Estrogen-Dependent Diseases. J. Med. Chem. 2017, 60 (9), 4086-4092. 46. Stanway, S. J.; Purohit, A.; Woo, L. W. L.; Sufi, S.; Vigushin, D.; Ward, R.; Wilson, R. H.; Stanczyk, F. Z.; Dobbs, N.; Kulinskaya, E.; Elliott, M.; Potter, B. V. L.; Reed, M. J.; Coombes, R. C., Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor. Clin. Cancer Res. 2006, 12 (5), 1585-1592. 47. Reed, M. J. P., B.V.L., Compounds that inhibit oestrone sulphatase and/or aromatase and methods for making and using. U.S. Pat. Appl. US 6506792 2003. 48. Hejaz, H. A. M.; Woo, L. W. L.; Purohit, A.; Reed, M. J.; Potter, B. V. L., Synthesis, in vitro and in vivo activity of benzophenone-based inhibitors of steroid sulfatase. Bioorg. Med. Chem. 2004, 12 (10), 2759-2772. 49. Woo, L. W. L.; Jackson, T.; Putey, A.; Cozier, G.; Leonard, P.; Acharya, K. R.; Chander, S. K.; Purohit, A.; Reed, M. J.; Potter, B. V. L., Highly Potent First Examples of Dual Aromatase−Steroid Sulfatase Inhibitors based on a Biphenyl Template. J. Med. Chem. 2010, 53 (5), 2155-2170. 50. Ahmed, S.; James, K.; Owen, C. P.; Patel, C. K.; Patel, M., Novel inhibitors of the enzyme estrone sulfatase (ES). Bioorg. Med. Chem. Lett. 2001, 11 (6), 841-844. 51. Ahmed, C. P. O. C. K. P. T. C. S., Synthesis and In Vitro Biochemical Evaluation of a Series of Cycloalkyl Esters of 4-Sulfamoylated Benzoic Acid as Inhibitors of Estrone Sulfatase (ES) Bentham Science Publishers 2007, 399-403(5). 52. Patel, C. K.; Owen, C. P.; Ahmed, S., Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg. Med. Chem. Lett. 2004, 14 (3), 605-609. 53. P. Owen, C.; Patel, M.; K Patel, C.; Cartledge, T.; Ahmed, S., Synthesis and In Vitro Biochemical Evaluation of a Series of Compounds as Potential Inhibitors of Estrone Sulfatase (ES) and the Role of pKa in both the Synthesis and the Inhibitory Activity of the Potential Inhibitors. 2007; Vol. 4, p 394-398. 54. Okada, M.; Nakagawa, T.; Iwashita, S.; Takegawa, S.; Fujii, T.; Koizumi, N., Development of novel steroid sulfatase inhibitors: I. Synthesis and biological evaluation of biphenyl-4-O-sulfamates. J. Steroid Biochem. Mol. Biol. 2003, 87 (2), 141-148. 55. Nussbaumer, P.; Winiski, A. P.; Billich, A., Estrogenic Potential of 2-Alkyl-4-(thio)chromenone 6-O-Sulfamates: Potent Inhibitors of Human Steroid Sulfatase. J. Med. Chem. 2003, 46 (23), 5091-5094. 56. Nussbaumer, P.; Bilban, M.; Billich, A., 4,4′-Benzophenone-O,O′-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg. Med. Chem. Lett. 2002, 12 (16), 2093-2095. 57. Ciobanu, L. C.; Luu-The, V.; Poirier, D., Nonsteroidal compounds designed to mimic potent steroid sulfatase inhibitors. J. Steroid Biochem. Mol. Biol. 2002, 80 (3), 339-353. 58. Fournier, D.; Breuil, P.-A.; Poirier, D., Synthesis of aryl sulfamate and phenol small peptide derivatives using a multidetachable sulfamate linker strategy. In Peptides for Youth: The Proceedings of the 20th American Peptide Symposium, Valle, S. D.; Escher, E.; Lubell, W. D., Eds. Springer New York: New York, NY, 2009; pp 219-220. 59. Lafay, J. R., B.; Carniato, D.; Bonnet, P.; Clerc, T.; Shields, J., et al., Sulfamate benzothiophene derivatives as steroid sulfatase inhibitors. U.S. Pat. Appl. US 2007021492 A1 2007. 60. Nussbaumer, P.; Billich, A., Steroid sulfatase inhibitors. Med. Res. Rev. 2004, 24 (4), 529-576. 61. Palmieri, C.; Januszewski, A.; Stanway, S.; Coombes, R. C., Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer. Expert Rev. Anticancer Ther. 2011, 11 (2), 179-183. 62. Hng, Y., Design and Synthesis of 3-Benzylaminocoumarin-7-O-Sulfamate Derivatives as Steroid Sulfatase Inhibitors. National Taiwan University Master Thesis 2016. 63. Bauer, K.; Elger, W.; Schneider, B.; Krahl, E.; Bauer, R., Effect of estradiol sulfamate (ES-J995) on affinity of hemoglobin for oxygen, cardiovascular function and acid-base balance in ovariectomized rats. Exp. Toxicol. Pathol. 2003, 55 (4), 301-307. 64. Elger, W.; Schwarz, S.; Hedden, A.; Reddersen, G.; Schneider, B., Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J. Steroid Biochem. Mol. Biol. 1995, 55 (3), 395-403. 65. De Vos, F.; Dumont, F.; Santens, P.; Slegers, G.; Dierckx, R. A.; De Reuck, J., Synthesis of two dopamine D4 receptor ligands: 11C labelled chromeno[3,4-c]pyridin-5-ones. J. Labelled Compd. Radiopharm. 2000, 43 (10), 989-996. 66. Staelens, L.; Oltenfreiter, R.; Cornelissen, B.; Blanckaert, P.; De Vos, F.; Deforce, D.; Dierckx, R. A.; Slegers, G., Synthesis of [123I]-3-(4-iodobenzyl)-1,2,3,4-tetrahydro-8-hydroxychromeno[3,4-c]pyridin-5-one, a potential dopamine D4 ligand for SPECT studies. J. Labelled Compd. Radiopharm. 2005, 48 (2), 101-108. 67. Okada, M.; Iwashita, S.; Koizumi, N., Efficient general method for sulfamoylation of a hydroxyl group. Tetrahedron Letters 2000, 41 (36), 7047-7051. 68. Lepage, O.; Stone, C.; Deslongchamps, P., Nazarov Reagents for Convergent and Expedient Synthesis of New Steroids. Org. Lett. 2002, 4 (7), 1091-1094. 69. Collins, D.; Jhingran, A.; Rutschmann, S., Enolic Ortho Esters. IV. Synthesis of the 8α and 8β Epimers of a 6-Oxa Steroidal Enolic Ortho Ester. Aust. J. Chem. 1989, 42 (10), 1769-1784. 70. Okada, M.; Iwashita, S.; Koizumi, N., Efficient general method for sulfamoylation of a hydroxyl group. Tetrahedron Lett. 2000, 41 (36), 7047-7051. 71. Chiba, M.; Pang, K. S., Effect of protein binding on 4-methylumbelliferyl sulfate desulfation kinetics in perfused rat liver. J. Pharmacol. Exp. Ther. 1993, 266 (2), 492-499. 72. Pasqualini, J. R.; Schatz, B.; Varin, C.; Nguyen, B. L., Recent data on estrogen sulfatases and sulfotransferases activities in human breast cancer. J. Steroid Biochem. Mol. Biol. 1992, 41 (3), 323-329. 73. OECD, Test No. 117: Partition Coefficient (n-octanol/water), HPLC Method. OECD Publishing. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20351 | - |
| dc.description.abstract | 類固醇硫酸酯酶 (steroid sulfatase, STS)一般存在於人體組織器官中，可以調節雌酮硫酸鹽 (estrone sulfate, E1S)及硫酸脫氫表雄酮 (dehydroepiandrosterone sulfate, DHEAS)轉化為具活性的雌激素酮 (estrone, E1)及脫氫表雄酮 (dehydroepiandrosterone, DHEA)。相較於正常細胞，ERα+乳癌腫瘤組織之類固醇硫酸酯酶會大量表現，造成癌細胞的增生，因此，抑制類固醇硫酸酯酶可以間接降低類固醇雌激素含量，進而減少乳癌細胞的增生，達到治癒乳癌的效果。
研究顯示香豆素胺基磺酸鹽類 (coumarin-based sulfamates)的化合物可有效抑制類固醇硫酸酯酶的活性，而在先前的研究中發現，3-benzylaminocoumarin-7-O-sulfamates衍生物對於人類胎盤類固醇硫酸酯酶具有抑制效果，且以coumarin為核心之化合物對其3號位置進行衍生化可增加活性。因此在本研究中，試著針對coumarin進行擴環合成出兩系列化合物，第一系列之化合物為針對coumarin進行環的限制修飾所合成出之三環化合物56a–n。結果顯示，以三環化合物56為核心對苯環3號位進行修飾可以增加抑制類固醇硫酸酯酶的效果，其中以化合物56b活性最佳，對於人類胎盤及MCF-7細胞類固醇硫酸酯酶之IC50分別為0.95 nM及0.38 μM。另外，第二系列之化合物65為E1S之類似物，其同樣具有理想的抑制效果，對於人類胎盤及MCF-7細胞類固醇硫酸酯酶之IC50分別為2.98 nM及0.55 μM。 本研究證實針對coumarin進行環的限制修飾可以有效增加化合物對類固醇硫酸酯酶的作用，達到更佳的抑制活性。 | zh_TW |
| dc.description.abstract | Steroid sulfatase (STS) is one enzyme responsible for the hydrolysis of biological inactive estrone sulfate (E1S) and dehydroepiandrosterone sulfate (DHEAS) to the corresponding active estrone (E1) and dehydroepiandrosterone (DHEA), which could convert to steroids that exhibit estrogenic properties. STS is present in several human tissues and organs. Compared to the normal tissues, there are raised levels of STS in estrogen receptor-positive breast cancer, promoting the proliferation of cancer cells. Therefore, inhibiting the activity of STS will decrease the level of estrogenic hormones and inhibit the proliferation and development of breast cancer.
Many studies have shown that coumarin-based sulfamate derivatives are potent STS inhibitors. In the previous work, we found that 3-benzylaminocoumarin-7-O-sulfamate derivatives could inhibit STS. Furthermore, structure modification at 3-position of coumarin could increase the activity of inhibition. As a result, in this study, two series of ring expansion were accomplished at 3, 4-positions of coumarin. First one was additional ring restriction coumarin to give tricycle compound 56a–n. The inhibitory activities of 56a–n were tested against MCF-7 cells and purified STS that was extracted from human placenta. Structure activity relationship (SAR) analysis revealed that the modification at 3-position of benzene ring improved inhibitory activity, where 56b was found to have the highest inhibitory activity against human placenta STS (IC50 = 0.95 nM) and MCF-7 cells STS (IC50 = 0.38 μM). The second series of compound was the mimic of E1S to provide compound 65, which was found to have good inhibitory activity against human placenta STS (IC50 = 2.98 nM) and MCF-7 cells STS (IC50 = 0.55 μM). Our results confirmed that the ring expansion of coumarin could increase the interaction between the inhibitors and STS, resulting in the better inhibitory activity. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T02:45:58Z (GMT). No. of bitstreams: 1 ntu-106-R04423002-1.pdf: 7017146 bytes, checksum: de8e80598a5c508fe8c1aa1e04cc3bd3 (MD5) Previous issue date: 2017 | en |
| dc.description.tableofcontents | 口試委員審定書 i
致謝 ii 中文摘要 iii Abstract iv 圖目錄 ix 表目錄 x 反應途徑目錄 xi 縮寫表 xii 第一章、簡介 1 1.1 賀爾蒙受體陽性乳癌 1 1.2 雌激素造成癌症之機轉 2 1.3 雌激素之生合成 3 1.4 賀爾蒙受體陽性乳癌之藥物治療 4 1.4.1 SERMs 4 1.4.2 AIs 5 1.4.3 SERMs及AIs之臨床使用及限制 5 1.5 類固醇硫酸酯酶 5 1.5.1類固醇硫酸酯酶之位置 5 1.5.2 類固醇硫酸酯酶之構造 6 1.5.3 類固醇硫酸酯酶之受質 7 1.5.4 類固醇硫酸酯酶之作用機轉 8 1.5.5 類固醇硫酸酯酶與乳癌 9 1.6 類固醇硫酸酯酶抑制劑的發展 9 1.6.1 類固醇胺基磺酸鹽類抑制劑 9 1.6.2 非類固醇胺基磺酸鹽類抑制劑 13 第二章、研究動機與目的 19 2.1 研究動機 19 2.2 胺基磺酸鹽類抑制劑之構效關係 19 2.3 先前研究之成果 20 2.3.1 設計理念 20 2.3.2 抑制活性 21 2.4 針對化合物49結構修飾之設計策略 23 2.5 sulfamate moiety於人體之穩定性 24 第三章、結果與討論 25 3.1 化學合成 25 3.1.1 化合物56a-n之合成 25 3.1.2 化合物65之合成 30 3.2 生物實驗 32 3.2.1 類固醇硫酸酯酶Km計算 32 3.2.2 類固醇硫酸酯酶抑制活性測試 34 3.3 電腦模擬 39 第四章、總結 42 第五章、實驗部分 43 5.1 試劑 43 5.2 實驗儀器 45 5.3 Bioassay 47 5.3.1 實驗器材 47 5.3.2 人類胎盤類固醇硫酸酯酶之萃取與純化 48 5.3.3 MCF-7細胞培養 48 5.3.4 人類胎盤類固醇硫酸酯酶Km測試 49 5.3.5 藥物對人類胎盤類固醇硫酸酯酶的抑制活性測試 49 5.3.6 藥物對MCF-7細胞類固醇硫酸酯酶的抑制活性測試 49 5.3.7 藥物對人類胎盤類固醇硫酸酯酶的親和性測試 50 5.3.8 Measurement of log P 50 5.4 Compounds preparation 51 5.4.1 8-hydroxy-1,2,3,4-tetrahydro-5H-chromeno[3,4-c]pyridin-5-one 51 5.4.2 General procedure A for reductive amination 51 5.4.3 General procedure B for sulfamoylation 61 References 73 Appendix I | - |
| dc.language.iso | zh_TW | - |
| dc.subject | 乳癌 | zh_TW |
| dc.subject | 擴環衍生物 | zh_TW |
| dc.subject | 香豆素-7-胺基磺酸鹽 | zh_TW |
| dc.subject | 類固醇硫酸酯?抑制劑 | zh_TW |
| dc.subject | 賀爾蒙受體陽性乳癌 | zh_TW |
| dc.subject | 乳癌 | zh_TW |
| dc.subject | 賀爾蒙受體陽性乳癌 | zh_TW |
| dc.subject | 類固醇硫酸酯?抑制劑 | zh_TW |
| dc.subject | 香豆素-7-胺基磺酸鹽 | zh_TW |
| dc.subject | 擴環衍生物 | zh_TW |
| dc.subject | steroid sulfatase inhibitors | en |
| dc.subject | ring expansion | en |
| dc.subject | coumarin-7-sulfamates derivatives | en |
| dc.subject | steroid sulfatase inhibitors | en |
| dc.subject | hormone-receptor-positive breast cancer | en |
| dc.subject | breast cancer | en |
| dc.subject | ring expansion | en |
| dc.subject | coumarin-7-sulfamates derivatives | en |
| dc.subject | breast cancer | en |
| dc.subject | hormone-receptor-positive breast cancer | en |
| dc.title | 合成香豆素-7-胺基磺酸 3、4號位擴環衍生物作為類固醇硫酸酯酶抑制劑及其活性探討 | zh_TW |
| dc.title | Synthesis and Biological Evaluation of Coumarin-7-Sulfamates with Ring Expansion at 3, 4-positions as Steroid Sulfatase Inhibitors | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 106-1 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 陳基旺;忻凌偉;劉得任 | zh_TW |
| dc.contributor.oralexamcommittee | ;; | en |
| dc.subject.keyword | 乳癌,賀爾蒙受體陽性乳癌,類固醇硫酸酯?抑制劑,香豆素-7-胺基磺酸鹽,擴環衍生物, | zh_TW |
| dc.subject.keyword | breast cancer,hormone-receptor-positive breast cancer,steroid sulfatase inhibitors,coumarin-7-sulfamates derivatives,ring expansion, | en |
| dc.relation.page | 127 | - |
| dc.identifier.doi | 10.6342/NTU201704291 | - |
| dc.rights.note | 未授權 | - |
| dc.date.accepted | 2017-10-19 | - |
| dc.contributor.author-college | 醫學院 | - |
| dc.contributor.author-dept | 藥學研究所 | - |
| 顯示於系所單位： | 藥學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-106-1.pdf 未授權公開取用 | 6.85 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。